Literature DB >> 17178767

Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.

Takuro Endo1, Masaaki Ban, Kazuma Hirata, Akitoshi Yamamoto, Yoshiki Hara, Yasunori Momose.   

Abstract

Pilocarpine is a cholinergic agonist that is metabolized to pilocarpic acid by serum esterase. In this study, we discovered a novel metabolite in human urine after the oral administration of pilocarpine hydrochloride, and we investigated the metabolic enzyme responsible for the metabolite formation. The structure of the metabolite was identified as 3-hydroxypilocarpine by liquid chromatography-tandem mass spectrometry and NMR analyses and by comparing to the authentic metabolite. To clarify the human cytochrome P450 (P450) responsible for the metabolite formation, in vitro experiments using P450 isoform-selective inhibitors, cDNA-expressed human P450s (Supersomes; CYP1A2, -2A6, -2B6, -2C9, -2C19, -2D6, -2E1, and -3A4), and liver microsomes from different donors were conducted. The formation of 3-hydroxypilocarpine in human liver microsomes was strongly inhibited (>90%) by 200 microM coumarin. Other selective inhibitors of CYP1A2 (furafylline and alpha-naphthoflavone), CYP2C9 (sulfaphenazole), CYP2C19 [(S)-mephenytoin], CYP2E1 (4-methylpyrazole), CYP2D6 (quinidine), and CYP3A4 (troleandomycin) had a weak inhibitory effect (<20%) on the formation. The highest formation activity was expressed by recombinant CYP2A6. The K(m) value for recombinant CYP2A6 was 3.1 microM, and this value is comparable with that of human liver microsomes (1.5 microM). The pilocarpine 3-hydroxylation activity was correlated with coumarin 7-hydroxylation activity in 16 human liver microsomes (r = 0.98). These data indicated that CYP2A6 is the main enzyme responsible for the 3-hydroxylation of pilocarpine. In conclusion, we identified a novel metabolite of pilocarpine, 3-hydroxypilocarpine, and we clarified the involvement of CYP2A6 in the formation of this molecule in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178767     DOI: 10.1124/dmd.106.013425

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.

Authors:  Julie-Anne Tanner; Bhagwat Prasad; Katrina G Claw; Patricia Stapleton; Amarjit Chaudhry; Erin G Schuetz; Kenneth E Thummel; Rachel F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2016-11-04       Impact factor: 4.030

2.  Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.

Authors:  Yune-Fang Ueng; Chien-Chih Chen; Yu-Ting Chung; Tsung-Yun Liu; Yu-Ping Chang; Wei-Sheng Lo; Norie Murayama; Hiroshi Yamazaki; Pavel Souček; Gar-Yang Chau; Chin-Wen Chi; Ruei-Ming Chen; Ding-Tzai Li
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 3.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

Review 4.  Variation in CYP2A6 Activity and Personalized Medicine.

Authors:  Julie-Anne Tanner; Rachel F Tyndale
Journal:  J Pers Med       Date:  2017-12-01

5.  Maximum human objectively measured pharmacologically stimulated accommodative amplitude.

Authors:  Andrzej Grzybowski; Ronald A Schachar; Magdalena Gaca-Wysocka; Ira H Schachar; Barbara K Pierscionek
Journal:  Clin Ophthalmol       Date:  2018-01-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.